F

Fennec Pharmaceuticals Inc
TSX:FRX

Watchlist Manager
Fennec Pharmaceuticals Inc
TSX:FRX
Watchlist
Price: 10.66 CAD
Market Cap: 291.3m CAD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+66%
Revenue
Forecast
+26%
Operating Income
Forecast
+158%
Net Income
Forecast
N/A

Wall Street
Price Targets

FRX Price Targets Summary
Fennec Pharmaceuticals Inc

Wall Street analysts forecast FRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FRX is 17.71 CAD with a low forecast of 13.7 CAD and a high forecast of 21.36 CAD.

FRX Lowest Forecast
Wall Street Target
13.7 CAD
28% Upside
FRX Average Forecast
Wall Street Target
17.71 CAD
66% Upside
FRX Highest Forecast
Wall Street Target
21.36 CAD
100% Upside
Lowest
Price Target
13.7 CAD
28% Upside
Average
Price Target
17.71 CAD
66% Upside
Highest
Price Target
21.36 CAD
100% Upside
Fennec Pharmaceuticals Inc Competitors:
Price Targets
BBIO
BridgeBio Pharma Inc
48% Upside
4593
Healios KK
13% Downside
XGN
Exagen Inc
7% Upside
A
ARMP
Armata Pharmaceuticals Inc
381% Upside
BBIO
BridgeBio Pharma Inc
48% Upside
4593
Healios KK
13% Downside
XGN
Exagen Inc
7% Upside
A
ARMP
Armata Pharmaceuticals Inc
381% Upside
AUPH
Aurinia Pharmaceuticals Inc
33% Upside
ALNY
Alnylam Pharmaceuticals Inc
7% Upside
300841
Chengdu Kanghua Biological Products Co Ltd
29% Upside
PTCT
PTC Therapeutics Inc
24% Upside

Revenue
Forecast

Revenue Estimate
Fennec Pharmaceuticals Inc

The compound annual growth rate of Fennec Pharmaceuticals Inc's revenue for the next 3 years is 26%.

N/A
Past Growth
26%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Fennec Pharmaceuticals Inc

The compound annual growth rate of Fennec Pharmaceuticals Inc's operating income for the next 3 years is 158%.

N/A
Past Growth
158%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Fennec Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
What are analyst estimates?

See Also

Summary
FRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
FRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FRX stock valuation using valuation multiples.
Wall Street Estimates
FRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FRX's stock price target?
Price Target
17.71 CAD

According to Wall Street analysts, the average 1-year price target for FRX is 17.71 CAD with a low forecast of 13.7 CAD and a high forecast of 21.36 CAD.

What is Fennec Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
26%

The compound annual growth rate of Fennec Pharmaceuticals Inc's revenue for the next 3 years is 26%.

What is Fennec Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
158%

The compound annual growth rate of Fennec Pharmaceuticals Inc's operating income for the next 3 years is 158%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.